Fulgent Genetics has entered into a definitive agreement to acquire selected assets of Bako Diagnostics, a pathology laboratory based in Alpharetta, GA, and to acquire StrataDx, a dermatopathology laboratory located in Lexington, MA, for a total combined purchase price of approximately $55.5 million, to be paid from cash on hand. The proposed acquisitions are expected to add new anatomic pathology services, proprietary PCR tests, and a national client base to Fulgent’s laboratory services platform. The transaction is anticipated to close during the first half of 2026, pending satisfaction of customary closing conditions. According to Ted Hull, CEO of Bako and StrataDx, the collaboration will bring together advanced technology, digital capabilities, and specialized expertise to enhance diagnostic solutions and the client experience.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fulgent Genetics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251222736495) on December 22, 2025, and is solely responsible for the information contained therein.